(Daily Wire) A clinical investigator of the drug commonly used off-label to block puberty in trans-identifying adolescents voiced his concerns about administering the drug without conducting proper safety tests.

Dr. Marc B. Garnick, a Harvard professor, oncologist, and co-principal investigator for the drug Lupron, wrote a letter to the editor of the New York Times in support of a recent investigation into the health effects of puberty blocker drugs for adolescents experiencing gender dysphoria.

“The scholarly and well-researched article raises significant safety issues about using puberty blockers in prepubescent and pubescent children as part of gender transitioning,” Garnick argued.

The letter was one of four accepted in response to the NYT article that described the “long-term physical effects and other consequences” of puberty blockers prescribed to adolescents experiencing gender distress. The other three letters, which were not written by medical professionals, criticized the article as “transphobic.”